Alpha Crest Capital Management LLC Kura Oncology, Inc. Transaction History

Alpha Crest Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$12.01 - $19.45 $311,899 - $505,116	25,970 Added 141.1%	44,375 $606,000
Q2 2022 Aug 11, 2022	SELL	$10.71 - $18.33 $97,471 - $166,821	-9,101 Reduced 33.09%	18,405 $337,000
Q1 2022 May 12, 2022	SELL	$11.78 - $16.98 $373,131 - $537,841	-31,675 Reduced 53.52%	27,506 $442,000
Q4 2021 Feb 09, 2022	BUY	$12.22 - $19.57 $563,109 - $901,805	46,081 Added 351.76%	59,181 $829,000
Q3 2021 Nov 10, 2021	SELL	$15.42 - $21.72 $820,344 - $1.16 Million	-53,200 Reduced 80.24%	13,100 $245,000
Q2 2021 Aug 12, 2021	BUY	$20.85 - $29.88 $808,980 - $1.16 Million	38,800 Added 141.09%	66,300 $1.38 Million
Q1 2021 May 13, 2021	BUY	$24.75 - $39.14 $680,625 - $1.08 Million	27,500 New	27,500 $777,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $603M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.